Reproxalap ‐ A Novel Treatment Option for Allergic Conjunctivitis – A Comprehensive Narrative Review
Sanila Mughal, Roshanay Ejaz Awan, Hur Abbas, Zahra Sania, Ashna Habib, Syeda Kaneez Sakina, Amina Mahmud, Mohammed Mahmmoud Fadelallah Eljack · 2026
Read Reproxalap ‐ A Novel Treatment Option for Allergic Conjunctivitis – A Comprehensive Narrative Review by Sanila Mughal, Roshanay Ejaz Awan, Hur Abbas, Zahra Sania, Ashna Habib, Syeda Kaneez Sakina, Amina Mahmud, Mohammed Mahmmoud Fadelallah Eljack (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13240090.txt.
Description
Sanila Mughal and co-authors review a new eye drop for allergic conjunctivitis in a 2026 narrative article. The condition reddens and itches the eyes of up to a fifth of the world's people, and existing treatments can be inconsistent or carry side effects with long use.
The drug, reproxalap, is the first of a class that traps reactive aldehyde species, unstable molecules that fan inflammation. Phase two and three trials found itch scores improved significantly, relief began early, and benefit held with continued use. Side effects were few. The authors present the drug as a promising alternative that may also suit other inflammatory eye conditions.
Catalog record
| CREATOR | Sanila Mughal, Roshanay Ejaz Awan, Hur Abbas, Zahra Sania, Ashna Habib, Syeda Kaneez Sakina, Amina Mahmud, Mohammed Mahmmoud Fadelallah Eljack |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 88 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |